Long-Term Safety And Efficacy Of Add-on Cannabidiol (CBD) Treatment in Patients With Lennox-Gastaut Syndrome In An Open-Label Extension Trial (GWPCARE5)

被引：0
|
作者：
Chin, R. [1 ]
Patel, A. [2 ]
Gil-Nagel, A. [3 ]
Mitchell, W. [4 ]
Perry, M. S. [5 ]
Weinstock, A. [6 ]
Whyte, L. [7 ]
VanLandingham, K. [8 ]
机构：
[1] Royal Hosp Sick Children, Edinburgh, Midlothian, Scotland
[2] Nationwide Childrens Hosp, Columbus, OH USA
[3] Hosp Ruber Int, Madrid, Spain
[4] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[5] Cook Childrens Med Ctr, Ft Worth, TX USA
[6] Oishei Childrens Hosp, Buffalo, NY USA
[7] GW Res Ltd, Cambridge, England
[8] Greenwich Biosci Inc, Carlsbad, CA USA
来源：
EPILEPSIA | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P119
引用
收藏
页码：63 / 64
页数：2
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5)
    Patel, Anup
    Gil-Nagel, Antonio
    Chin, Richard
    Mitchell, Wendy
    Perry, M. Scott
    Weinstock, Arie
    Roberts, Claire
    Whyte, Lauren
    VanLandingham, Kevan
    [J]. NEUROLOGY, 2019, 92 (15)
  • [2] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome (LGS) in an Open-Label Extension (OLE) Trial (GWPCARE5)
    Perry, M.
    Patel, A.
    Gil-Nagel, A.
    Chin, R.
    Mitchell, W.
    Weinstock, A.
    VanLandingham, K.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S76 - S77
  • [3] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results from Open-label Extension Trial (GWPCARE5)
    Halford, Jonathan
    Marsh, Eric
    Mazurkiewicz-Beldzinska, Maria
    Gunning, Boudewjin
    Checketts, Daniel
    Roberts, Claire
    Thiele, Elizabeth
    [J]. NEUROLOGY, 2018, 90
  • [4] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results of the Open-label Extension (OLE) Trial (GWPCARE5)
    Thiele, E.
    Marsh, E.
    Halford, J.
    Mazurkiewicz-Beldzinska, M.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    [J]. ANNALS OF NEUROLOGY, 2018, 84 : S336 - S336
  • [5] Maintained Safety and Efficacy of Cannabidiol in a Long-Term Open-Label Trial in Patients with Lennox-Gastaut Syndrome (GWPCARE5)
    Marsh, E.
    Mazurkiewicz-Beldzinska, M.
    Halford, J.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    Thiele, E.
    [J]. EPILEPSIA, 2018, 59 : S9 - S9
  • [6] Long-Term Safety And Efficacy Of Add-On Cannabidiol (CBD) Treatment In Patients With Dravet Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Nabbout, R.
    Halford, J.
    Scheffer, I. E.
    Sanchez-Carpintero, R.
    Malawsky, Y. Shiloh
    Wong, M.
    Checketts, D.
    VanLandingham, K.
    [J]. EPILEPSIA, 2019, 60 : 63 - 63
  • [7] Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
    Patel, Anup D.
    Mazurkiewicz-Beldzinska, Maria
    Chin, Richard F.
    Gil-Nagel, Antonio
    Gunning, Boudewijn
    Halford, Jonathan J.
    Mitchell, Wendy
    Scott Perry, Michael
    Thiele, Elizabeth A.
    Weinstock, Arie
    Dunayevich, Eduardo
    Checketts, Daniel
    Devinsky, Orrin
    [J]. EPILEPSIA, 2021, 62 (09) : 2228 - 2239
  • [8] Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5)
    Patel, Anup
    Chin, Richard
    Mitchell, Wendy
    Perry, Scott
    Weinstock, Arie
    Checketts, Daniel
    Dunayevich, Eduardo
    [J]. NEUROLOGY, 2020, 94 (15)
  • [9] Long-term safety and efficacy of Cannabidiol (CBD) treatment in Lennox Gastaut syndrome: results overall and for patients completing 1-3 years of an open-label extension (GWPCARE5)
    Chin, R.
    Gil-Nagel, A.
    Mitchell, W.
    Patel, A. D.
    Perry, M. S.
    Weinstock, A.
    Checketts, D.
    Dunayevich, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 24 - 24
  • [10] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an open-label, Extension Trial
    Halford, Jonathan
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawsky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    VanLandingham, Kevan
    [J]. NEUROLOGY, 2019, 92 (15)
12345